New Insulin Preparations: Potential Benefits And Risk Assessments

Concentrated insulins have been especially problematic high alert medications. On February 25, 2015 Federal Drug Administration (FDA) approval made available insulin glargine, Toujeo U-300 (300 units/ml) in a SoloSTAR pen. On May 27, 2015 the FDA approved insulin lispro, Humalog U-200 (200 units/ml) KwikPen. Increased incidence of insulin resistant type 2 diabetes has escalated the need for concentrated insulin. This paper discusses each insulin, appropriate patient selection, benefits of the new insulins for people with diabetes and providers, and suggestions for prevention of potential off-label use of insulin pens. Counseling and assessment are essential to avoid unintended harm.